Literature DB >> 16307354

Co-administration of ketoconazole and tacrolimus therapy: a transplanted rat model.

Nashwa Barakat1, Alaa Sabry, Amgad El-Agroudy, Samia Hawas, Mahmoud Abdel-Maboud, Mahasen A El-Shair, M A Ghoneim.   

Abstract

BACKGROUND/AIM: The aim of this work is to study the safety and the effect of addition of ketoconazole to experimental kidney transplanted rat treated with tacrolimus and predicts the percentage of tacrolimus dose reduction.
MATERIAL AND METHODS: The material of this work included 60 male Sprague Dawely rats subjected to renal allotransplantation. They were equally divided into five groups: Group I: served as control group, Group II: received FK506 3.2 mg/kg/bw, Group III: received FK506 2 mg/kg/bw, Group IV: received FK506 1 mg/kg/bw, Group V: received FK506 1 mg/kg/bw plus Ketoconazole 20 mg/kg/day. FK506 trough level and laboratory investigations were determined at 0, 3, 7, 10, 14, and 27 days post-transplantation.
RESULTS: In all groups loss of body weight was observed at day 27 after treatment compared to that before transplantation. Serum creatinine significantly increased at day 27 compared to the basal level in groups treated with 1.0 and 3.2 mg FK506 (1.80 +/- 0.50 versus 0.39 +/- 0.06 P = 0.001) and (1.03 +/- 0.26 versus 0.50 +/- 0.07 P = 0.001) respectively, while for 2.0 mg or 1.0 mg plus keto groups, no significant differences in serum creatinine levels over time (0.56 +/- 0.22 versus 0.44 +/- 0.10 P = 0.106) and (0.55 +/- 0.30 versus 0.42 +/- 0.08 P=0.160) were observed.
CONCLUSION: Concomitant administration of Ketoconazole and FK506 in transplanted rat model is safe and results in increase of blood trough level concentration of FK506 with 50% reduction of its dose.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307354     DOI: 10.1007/s11255-005-2393-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  16 in total

1.  Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.

Authors:  A D Mayer; J Dmitrewski; J P Squifflet; T Besse; B Grabensee; B Klein; F W Eigler; U Heemann; R Pichlmayr; M Behrend; Y Vanrenterghem; J Donck; J van Hooff; M Christiaans; J M Morales; A Andres; R W Johnson; C Short; B Buchholz; N Rehmert; W Land; S Schleibner; J L Forsythe; D Talbot; E Pohanka
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

2.  High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients.

Authors:  U Christians; F Braun; N Kosian; M Schmidt; H M Schiebel; L Ernst; C Kruse; M Winkler; I Holze; A Linck
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine.

Authors:  H Jiang; T Fujitsu; S Sakuma; T Ogawa; K Tamura; Y Fujii; Y Akiyama; S Izumi; S Takahara; M Ishibashi
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

4.  Fluconazole therapy in transplant recipients receiving FK506.

Authors:  R Mañez; M Martin; D Raman; D Silverman; A Jain; V Warty; I Gonzalez-Pinto; S Kusne; T E Starzl
Journal:  Transplantation       Date:  1994-05-27       Impact factor: 4.939

5.  Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes.

Authors:  K Iwasaki; H Matsuda; K Nagase; T Shiraga; Y Tokuma; K Uchida
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-11

6.  Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation.

Authors:  K Hayakawa; M Hata; T Nishiyama; M Ohashi; M Ishikawa
Journal:  Transplant Proc       Date:  1996-06       Impact factor: 1.066

7.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

8.  Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.

Authors:  D J Newton; R W Wang; A Y Lu
Journal:  Drug Metab Dispos       Date:  1995-01       Impact factor: 3.922

9.  FK 506: long-term study in kidney transplantation. Japanese FK 506 Study Group.

Authors:  I Yokoyama; K Uchida; K Fukao; T Ochiai; K Takahashi; T Endo; S Oshima; M Ishibashi; S Takahara; Y Iwasaki
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

10.  Coadministration of ketoconazole and cyclosporine for kidney transplant recipients: long-term follow-up and study of metabolic consequences.

Authors:  M A Sobh; A F Hamdy; A E El Agroudy; K El Sayed; T El-Diasty; M A Bakr; M A Ghoneim
Journal:  Am J Kidney Dis       Date:  2001-03       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.